Natco Pharma gets CDSCO nod for generic semaglutide, launch in March 2026

Semaglutide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise.

Leave a Reply

Your email address will not be published. Required fields are marked *